Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to six new employees. The Compensation Committee approved stock options to purchase 28,600 shares at $17.33 per share (the closing price on October 23, 2024) and restricted stock units for 14,300 shares. These awards were granted under the company's 2020 Inducement Plan, which was approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie per il cancro, ha concesso premi azionari a sei nuovi dipendenti. Il Comitato per la Compensazione ha approvato opzioni per l'acquisto di 28.600 azioni a 17,33 dollari per azione (il prezzo di chiusura del 23 ottobre 2024) e unità di azioni vincolate per 14.300 azioni. Questi premi sono stati concessi nell'ambito del Piano di Induzione 2020 dell'azienda, che è stato approvato ai sensi dell'eccezione per inducement della Regola 303A.08 del Manuale delle Aziende quotate NYSE.
Arcus Biosciences (NYSE:RCUS), una empresa biofarmacéutica en etapa clínica enfocada en terapias contra el cáncer, ha otorgado premios de capital a seis nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones para comprar 28,600 acciones a 17.33 dólares por acción (el precio de cierre del 23 de octubre de 2024) y unidades de acciones restringidas para 14,300 acciones. Estos premios se otorgaron bajo el Plan de Inducción 2020 de la empresa, que fue aprobado bajo la excepción de inducción de la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE.
Arcus Biosciences (NYSE:RCUS), 암 치료에 집중하는 임상 단계의 생명공학 회사가 여섯 명의 신입 직원에게 주식 보상을 수여했습니다. 보상 위원회는 주당 17.33달러 (2024년 10월 23일 종가)에 28,600주를 매입할 수 있는 주식 옵션과 14,300주에 대한 제한 주식 유닛을 승인했습니다. 이 보상은 NYSE 상장 회사 매뉴얼 규칙 303A.08의 유도 예외에 따라 승인된 회사의 2020년 유도 계획에 따라 수여되었습니다.
Arcus Biosciences (NYSE:RCUS), une entreprise biopharmaceutique en phase clinique axée sur les thérapies anti-cancer, a accordé des récompenses en actions à six nouveaux employés. Le Comité de Rémunération a approuvé des options d'achat d'actions pour 28 600 actions à 17,33 dollars par action (le prix de clôture du 23 octobre 2024) et des unités d'actions restreintes pour 14 300 actions. Ces récompenses ont été accordées dans le cadre du Plan d'Induction 2020 de l'entreprise, qui a été approuvé en vertu de l'exception d'incitation de la Règle 303A.08 du Manuel des Sociétés Cotées de la NYSE.
Arcus Biosciences (NYSE:RCUS), ein biopharmazeutisches Unternehmen in klinischen Studien, das sich auf Krebstherapien spezialisiert hat, hat sechs neuen Mitarbeitern Eigenkapitalvergütungen gewährt. Der Vergütungsausschuss genehmigte Aktienoptionen zum Kauf von 28.600 Aktien zu je 17,33 USD pro Aktie (der Schlusskurs am 23. Oktober 2024) und beschränkte Aktieneinheiten für 14.300 Aktien. Diese Vergütungen wurden im Rahmen des Induktionsplans 2020 des Unternehmens gewährt, der gemäß der Induktionsausnahme der Regel 303A.08 des NYSE Listed Company Manual genehmigt wurde.
- None.
- None.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Inducement PR
Source: Arcus Biosciences
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024424382/en/
Investor Inquiries:
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
FAQ
How many shares were granted in Arcus Biosciences (RCUS) October 2024 inducement grants?
What was the exercise price for RCUS stock options granted on October 23, 2024?
Under which plan were RCUS's October 2024 equity awards granted?
